Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Peptide and Oligonucleotide CDMO Market Size Growth Rate by Type: 2018 VS 2022 VS 2033
1.2.2 Peptide CDMO
1.2.3 Oligonucleotide CDMO
1.3 Market by Application
1.3.1 Global Peptide and Oligonucleotide CDMO Market Growth by Application: 2018 VS 2022 VS 2033
1.3.2 Pharmaceutical and Biotechnology Companies
1.3.3 Research Institutes
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Peptide and Oligonucleotide CDMO Market Perspective (2018-2033)
2.2 Peptide and Oligonucleotide CDMO Growth Trends by Region
2.2.1 Global Peptide and Oligonucleotide CDMO Market Size by Region: 2018 VS 2022 VS 2033
2.2.2 Peptide and Oligonucleotide CDMO Historic Market Size by Region (2018-2023)
2.2.3 Peptide and Oligonucleotide CDMO Forecasted Market Size by Region (2024-2033)
2.3 Peptide and Oligonucleotide CDMO Market Dynamics
2.3.1 Peptide and Oligonucleotide CDMO Industry Trends
2.3.2 Peptide and Oligonucleotide CDMO Market Drivers
2.3.3 Peptide and Oligonucleotide CDMO Market Challenges
2.3.4 Peptide and Oligonucleotide CDMO Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Peptide and Oligonucleotide CDMO Players by Revenue
3.1.1 Global Top Peptide and Oligonucleotide CDMO Players by Revenue (2018-2023)
3.1.2 Global Peptide and Oligonucleotide CDMO Revenue Market Share by Players (2018-2023)
3.2 Global Peptide and Oligonucleotide CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Peptide and Oligonucleotide CDMO Revenue
3.4 Global Peptide and Oligonucleotide CDMO Market Concentration Ratio
3.4.1 Global Peptide and Oligonucleotide CDMO Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Peptide and Oligonucleotide CDMO Revenue in 2022
3.5 Peptide and Oligonucleotide CDMO Key Players Head office and Area Served
3.6 Key Players Peptide and Oligonucleotide CDMO Product Solution and Service
3.7 Date of Enter into Peptide and Oligonucleotide CDMO Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Peptide and Oligonucleotide CDMO Breakdown Data by Type
4.1 Global Peptide and Oligonucleotide CDMO Historic Market Size by Type (2018-2023)
4.2 Global Peptide and Oligonucleotide CDMO Forecasted Market Size by Type (2024-2033)
5 Peptide and Oligonucleotide CDMO Breakdown Data by Application
5.1 Global Peptide and Oligonucleotide CDMO Historic Market Size by Application (2018-2023)
5.2 Global Peptide and Oligonucleotide CDMO Forecasted Market Size by Application (2024-2033)
6 North America
6.1 North America Peptide and Oligonucleotide CDMO Market Size (2018-2033)
6.2 North America Peptide and Oligonucleotide CDMO Market Growth Rate by Country: 2018 VS 2022 VS 2033
6.3 North America Peptide and Oligonucleotide CDMO Market Size by Country (2018-2023)
6.4 North America Peptide and Oligonucleotide CDMO Market Size by Country (2024-2033)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Peptide and Oligonucleotide CDMO Market Size (2018-2033)
7.2 Europe Peptide and Oligonucleotide CDMO Market Growth Rate by Country: 2018 VS 2022 VS 2033
7.3 Europe Peptide and Oligonucleotide CDMO Market Size by Country (2018-2023)
7.4 Europe Peptide and Oligonucleotide CDMO Market Size by Country (2024-2033)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Peptide and Oligonucleotide CDMO Market Size (2018-2033)
8.2 Asia-Pacific Peptide and Oligonucleotide CDMO Market Growth Rate by Region: 2018 VS 2022 VS 2033
8.3 Asia-Pacific Peptide and Oligonucleotide CDMO Market Size by Region (2018-2023)
8.4 Asia-Pacific Peptide and Oligonucleotide CDMO Market Size by Region (2024-2033)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Peptide and Oligonucleotide CDMO Market Size (2018-2033)
9.2 Latin America Peptide and Oligonucleotide CDMO Market Growth Rate by Country: 2018 VS 2022 VS 2033
9.3 Latin America Peptide and Oligonucleotide CDMO Market Size by Country (2018-2023)
9.4 Latin America Peptide and Oligonucleotide CDMO Market Size by Country (2024-2033)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Peptide and Oligonucleotide CDMO Market Size (2018-2033)
10.2 Middle East & Africa Peptide and Oligonucleotide CDMO Market Growth Rate by Country: 2018 VS 2022 VS 2033
10.3 Middle East & Africa Peptide and Oligonucleotide CDMO Market Size by Country (2018-2023)
10.4 Middle East & Africa Peptide and Oligonucleotide CDMO Market Size by Country (2024-2033)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Lonza Group Ltd.
11.1.1 Lonza Group Ltd. Company Detail
11.1.2 Lonza Group Ltd. Business Overview
11.1.3 Lonza Group Ltd. Peptide and Oligonucleotide CDMO Introduction
11.1.4 Lonza Group Ltd. Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023)
11.1.5 Lonza Group Ltd. Recent Development
11.2 Thermo Fisher Scientific Inc.
11.2.1 Thermo Fisher Scientific Inc. Company Detail
11.2.2 Thermo Fisher Scientific Inc. Business Overview
11.2.3 Thermo Fisher Scientific Inc. Peptide and Oligonucleotide CDMO Introduction
11.2.4 Thermo Fisher Scientific Inc. Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023)
11.2.5 Thermo Fisher Scientific Inc. Recent Development
11.3 Merck KGaA
11.3.1 Merck KGaA Company Detail
11.3.2 Merck KGaA Business Overview
11.3.3 Merck KGaA Peptide and Oligonucleotide CDMO Introduction
11.3.4 Merck KGaA Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023)
11.3.5 Merck KGaA Recent Development
11.4 Catalent, Inc.
11.4.1 Catalent, Inc. Company Detail
11.4.2 Catalent, Inc. Business Overview
11.4.3 Catalent, Inc. Peptide and Oligonucleotide CDMO Introduction
11.4.4 Catalent, Inc. Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023)
11.4.5 Catalent, Inc. Recent Development
11.5 Genscript Biotech Corporation
11.5.1 Genscript Biotech Corporation Company Detail
11.5.2 Genscript Biotech Corporation Business Overview
11.5.3 Genscript Biotech Corporation Peptide and Oligonucleotide CDMO Introduction
11.5.4 Genscript Biotech Corporation Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023)
11.5.5 Genscript Biotech Corporation Recent Development
11.6 Polypeptide Group
11.6.1 Polypeptide Group Company Detail
11.6.2 Polypeptide Group Business Overview
11.6.3 Polypeptide Group Peptide and Oligonucleotide CDMO Introduction
11.6.4 Polypeptide Group Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023)
11.6.5 Polypeptide Group Recent Development
11.7 Bachem Holding AG
11.7.1 Bachem Holding AG Company Detail
11.7.2 Bachem Holding AG Business Overview
11.7.3 Bachem Holding AG Peptide and Oligonucleotide CDMO Introduction
11.7.4 Bachem Holding AG Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023)
11.7.5 Bachem Holding AG Recent Development
11.8 Wuxi Apptec Co., Ltd.
11.8.1 Wuxi Apptec Co., Ltd. Company Detail
11.8.2 Wuxi Apptec Co., Ltd. Business Overview
11.8.3 Wuxi Apptec Co., Ltd. Peptide and Oligonucleotide CDMO Introduction
11.8.4 Wuxi Apptec Co., Ltd. Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023)
11.8.5 Wuxi Apptec Co., Ltd. Recent Development
11.9 Ajinomoto Co., Inc.
11.9.1 Ajinomoto Co., Inc. Company Detail
11.9.2 Ajinomoto Co., Inc. Business Overview
11.9.3 Ajinomoto Co., Inc. Peptide and Oligonucleotide CDMO Introduction
11.9.4 Ajinomoto Co., Inc. Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023)
11.9.5 Ajinomoto Co., Inc. Recent Development
11.10 Rentschler Biopharma SE
11.10.1 Rentschler Biopharma SE Company Detail
11.10.2 Rentschler Biopharma SE Business Overview
11.10.3 Rentschler Biopharma SE Peptide and Oligonucleotide CDMO Introduction
11.10.4 Rentschler Biopharma SE Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023)
11.10.5 Rentschler Biopharma SE Recent Development
11.11 Corden Pharma GmbH
11.11.1 Corden Pharma GmbH Company Detail
11.11.2 Corden Pharma GmbH Business Overview
11.11.3 Corden Pharma GmbH Peptide and Oligonucleotide CDMO Introduction
11.11.4 Corden Pharma GmbH Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023)
11.11.5 Corden Pharma GmbH Recent Development
11.12 Senn Chemicals AG
11.12.1 Senn Chemicals AG Company Detail
11.12.2 Senn Chemicals AG Business Overview
11.12.3 Senn Chemicals AG Peptide and Oligonucleotide CDMO Introduction
11.12.4 Senn Chemicals AG Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023)
11.12.5 Senn Chemicals AG Recent Development
11.13 Almac Group
11.13.1 Almac Group Company Detail
11.13.2 Almac Group Business Overview
11.13.3 Almac Group Peptide and Oligonucleotide CDMO Introduction
11.13.4 Almac Group Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023)
11.13.5 Almac Group Recent Development
11.14 Lonza Custom Manufacturing
11.14.1 Lonza Custom Manufacturing Company Detail
11.14.2 Lonza Custom Manufacturing Business Overview
11.14.3 Lonza Custom Manufacturing Peptide and Oligonucleotide CDMO Introduction
11.14.4 Lonza Custom Manufacturing Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023)
11.14.5 Lonza Custom Manufacturing Recent Development
11.15 Creative Peptides
11.15.1 Creative Peptides Company Detail
11.15.2 Creative Peptides Business Overview
11.15.3 Creative Peptides Peptide and Oligonucleotide CDMO Introduction
11.15.4 Creative Peptides Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023)
11.15.5 Creative Peptides Recent Development
11.16 Swiss Customized Synthesis
11.16.1 Swiss Customized Synthesis Company Detail
11.16.2 Swiss Customized Synthesis Business Overview
11.16.3 Swiss Customized Synthesis Peptide and Oligonucleotide CDMO Introduction
11.16.4 Swiss Customized Synthesis Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023)
11.16.5 Swiss Customized Synthesis Recent Development
11.17 Syngene
11.17.1 Syngene Company Detail
11.17.2 Syngene Business Overview
11.17.3 Syngene Peptide and Oligonucleotide CDMO Introduction
11.17.4 Syngene Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023)
11.17.5 Syngene Recent Development
11.18 Eurogentec
11.18.1 Eurogentec Company Detail
11.18.2 Eurogentec Business Overview
11.18.3 Eurogentec Peptide and Oligonucleotide CDMO Introduction
11.18.4 Eurogentec Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023)
11.18.5 Eurogentec Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Peptide and Oligonucleotide CDMO Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2033
Table 2. Key Players of Peptide CDMO
Table 3. Key Players of Oligonucleotide CDMO
Table 4. Global Peptide and Oligonucleotide CDMO Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2033
Table 5. Global Peptide and Oligonucleotide CDMO Market Size by Region (US$ Million): 2018 VS 2022 VS 2033
Table 6. Global Peptide and Oligonucleotide CDMO Market Size by Region (2018-2023) & (US$ Million)
Table 7. Global Peptide and Oligonucleotide CDMO Market Share by Region (2018-2023)
Table 8. Global Peptide and Oligonucleotide CDMO Forecasted Market Size by Region (2024-2033) & (US$ Million)
Table 9. Global Peptide and Oligonucleotide CDMO Market Share by Region (2024-2033)
Table 10. Peptide and Oligonucleotide CDMO Market Trends
Table 11. Peptide and Oligonucleotide CDMO Market Drivers
Table 12. Peptide and Oligonucleotide CDMO Market Challenges
Table 13. Peptide and Oligonucleotide CDMO Market Restraints
Table 14. Global Peptide and Oligonucleotide CDMO Revenue by Players (2018-2023) & (US$ Million)
Table 15. Global Peptide and Oligonucleotide CDMO Market Share by Players (2018-2023)
Table 16. Global Top Peptide and Oligonucleotide CDMO Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Peptide and Oligonucleotide CDMO as of 2022)
Table 17. Ranking of Global Top Peptide and Oligonucleotide CDMO Companies by Revenue (US$ Million) in 2022
Table 18. Global 5 Largest Players Market Share by Peptide and Oligonucleotide CDMO Revenue (CR5 and HHI) & (2018-2023)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Peptide and Oligonucleotide CDMO Product Solution and Service
Table 21. Date of Enter into Peptide and Oligonucleotide CDMO Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Peptide and Oligonucleotide CDMO Market Size by Type (2018-2023) & (US$ Million)
Table 24. Global Peptide and Oligonucleotide CDMO Revenue Market Share by Type (2018-2023)
Table 25. Global Peptide and Oligonucleotide CDMO Forecasted Market Size by Type (2024-2033) & (US$ Million)
Table 26. Global Peptide and Oligonucleotide CDMO Revenue Market Share by Type (2024-2033)
Table 27. Global Peptide and Oligonucleotide CDMO Market Size by Application (2018-2023) & (US$ Million)
Table 28. Global Peptide and Oligonucleotide CDMO Revenue Market Share by Application (2018-2023)
Table 29. Global Peptide and Oligonucleotide CDMO Forecasted Market Size by Application (2024-2033) & (US$ Million)
Table 30. Global Peptide and Oligonucleotide CDMO Revenue Market Share by Application (2024-2033)
Table 31. North America Peptide and Oligonucleotide CDMO Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 32. North America Peptide and Oligonucleotide CDMO Market Size by Country (2018-2023) & (US$ Million)
Table 33. North America Peptide and Oligonucleotide CDMO Market Size by Country (2024-2033) & (US$ Million)
Table 34. Europe Peptide and Oligonucleotide CDMO Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 35. Europe Peptide and Oligonucleotide CDMO Market Size by Country (2018-2023) & (US$ Million)
Table 36. Europe Peptide and Oligonucleotide CDMO Market Size by Country (2024-2033) & (US$ Million)
Table 37. Asia-Pacific Peptide and Oligonucleotide CDMO Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2033
Table 38. Asia-Pacific Peptide and Oligonucleotide CDMO Market Size by Region (2018-2023) & (US$ Million)
Table 39. Asia-Pacific Peptide and Oligonucleotide CDMO Market Size by Region (2024-2033) & (US$ Million)
Table 40. Latin America Peptide and Oligonucleotide CDMO Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 41. Latin America Peptide and Oligonucleotide CDMO Market Size by Country (2018-2023) & (US$ Million)
Table 42. Latin America Peptide and Oligonucleotide CDMO Market Size by Country (2024-2033) & (US$ Million)
Table 43. Middle East & Africa Peptide and Oligonucleotide CDMO Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 44. Middle East & Africa Peptide and Oligonucleotide CDMO Market Size by Country (2018-2023) & (US$ Million)
Table 45. Middle East & Africa Peptide and Oligonucleotide CDMO Market Size by Country (2024-2033) & (US$ Million)
Table 46. Lonza Group Ltd. Company Detail
Table 47. Lonza Group Ltd. Business Overview
Table 48. Lonza Group Ltd. Peptide and Oligonucleotide CDMO Product
Table 49. Lonza Group Ltd. Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023) & (US$ Million)
Table 50. Lonza Group Ltd. Recent Development
Table 51. Thermo Fisher Scientific Inc. Company Detail
Table 52. Thermo Fisher Scientific Inc. Business Overview
Table 53. Thermo Fisher Scientific Inc. Peptide and Oligonucleotide CDMO Product
Table 54. Thermo Fisher Scientific Inc. Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023) & (US$ Million)
Table 55. Thermo Fisher Scientific Inc. Recent Development
Table 56. Merck KGaA Company Detail
Table 57. Merck KGaA Business Overview
Table 58. Merck KGaA Peptide and Oligonucleotide CDMO Product
Table 59. Merck KGaA Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023) & (US$ Million)
Table 60. Merck KGaA Recent Development
Table 61. Catalent, Inc. Company Detail
Table 62. Catalent, Inc. Business Overview
Table 63. Catalent, Inc. Peptide and Oligonucleotide CDMO Product
Table 64. Catalent, Inc. Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023) & (US$ Million)
Table 65. Catalent, Inc. Recent Development
Table 66. Genscript Biotech Corporation Company Detail
Table 67. Genscript Biotech Corporation Business Overview
Table 68. Genscript Biotech Corporation Peptide and Oligonucleotide CDMO Product
Table 69. Genscript Biotech Corporation Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023) & (US$ Million)
Table 70. Genscript Biotech Corporation Recent Development
Table 71. Polypeptide Group Company Detail
Table 72. Polypeptide Group Business Overview
Table 73. Polypeptide Group Peptide and Oligonucleotide CDMO Product
Table 74. Polypeptide Group Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023) & (US$ Million)
Table 75. Polypeptide Group Recent Development
Table 76. Bachem Holding AG Company Detail
Table 77. Bachem Holding AG Business Overview
Table 78. Bachem Holding AG Peptide and Oligonucleotide CDMO Product
Table 79. Bachem Holding AG Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023) & (US$ Million)
Table 80. Bachem Holding AG Recent Development
Table 81. Wuxi Apptec Co., Ltd. Company Detail
Table 82. Wuxi Apptec Co., Ltd. Business Overview
Table 83. Wuxi Apptec Co., Ltd. Peptide and Oligonucleotide CDMO Product
Table 84. Wuxi Apptec Co., Ltd. Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023) & (US$ Million)
Table 85. Wuxi Apptec Co., Ltd. Recent Development
Table 86. Ajinomoto Co., Inc. Company Detail
Table 87. Ajinomoto Co., Inc. Business Overview
Table 88. Ajinomoto Co., Inc. Peptide and Oligonucleotide CDMO Product
Table 89. Ajinomoto Co., Inc. Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023) & (US$ Million)
Table 90. Ajinomoto Co., Inc. Recent Development
Table 91. Rentschler Biopharma SE Company Detail
Table 92. Rentschler Biopharma SE Business Overview
Table 93. Rentschler Biopharma SE Peptide and Oligonucleotide CDMO Product
Table 94. Rentschler Biopharma SE Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023) & (US$ Million)
Table 95. Rentschler Biopharma SE Recent Development
Table 96. Corden Pharma GmbH Company Detail
Table 97. Corden Pharma GmbH Business Overview
Table 98. Corden Pharma GmbH Peptide and Oligonucleotide CDMO Product
Table 99. Corden Pharma GmbH Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023) & (US$ Million)
Table 100. Corden Pharma GmbH Recent Development
Table 101. Senn Chemicals AG Company Detail
Table 102. Senn Chemicals AG Business Overview
Table 103. Senn Chemicals AG Peptide and Oligonucleotide CDMO Product
Table 104. Senn Chemicals AG Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023) & (US$ Million)
Table 105. Senn Chemicals AG Recent Development
Table 106. Almac Group Company Detail
Table 107. Almac Group Business Overview
Table 108. Almac Group Peptide and Oligonucleotide CDMO Product
Table 109. Almac Group Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023) & (US$ Million)
Table 110. Almac Group Recent Development
Table 111. Lonza Custom Manufacturing Company Detail
Table 112. Lonza Custom Manufacturing Business Overview
Table 113. Lonza Custom Manufacturing Peptide and Oligonucleotide CDMO Product
Table 114. Lonza Custom Manufacturing Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023) & (US$ Million)
Table 115. Lonza Custom Manufacturing Recent Development
Table 116. Creative Peptides Company Detail
Table 117. Creative Peptides Business Overview
Table 118. Creative Peptides Peptide and Oligonucleotide CDMO Product
Table 119. Creative Peptides Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023) & (US$ Million)
Table 120. Creative Peptides Recent Development
Table 121. Swiss Customized Synthesis Company Detail
Table 122. Swiss Customized Synthesis Business Overview
Table 123. Swiss Customized Synthesis Peptide and Oligonucleotide CDMO Product
Table 124. Swiss Customized Synthesis Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023) & (US$ Million)
Table 125. Swiss Customized Synthesis Recent Development
Table 126. Syngene Company Detail
Table 127. Syngene Business Overview
Table 128. Syngene Peptide and Oligonucleotide CDMO Product
Table 129. Syngene Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023) & (US$ Million)
Table 130. Syngene Recent Development
Table 131. Eurogentec Company Detail
Table 132. Eurogentec Business Overview
Table 133. Eurogentec Peptide and Oligonucleotide CDMO Product
Table 134. Eurogentec Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023) & (US$ Million)
Table 135. Eurogentec Recent Development
Table 136. Research Programs/Design for This Report
Table 137. Key Data Information from Secondary Sources
Table 138. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Peptide and Oligonucleotide CDMO Market Size Comparison by Type (2023-2033) & (US$ Million)
Figure 2. Global Peptide and Oligonucleotide CDMO Market Share by Type: 2022 VS 2033
Figure 3. Peptide CDMO Features
Figure 4. Oligonucleotide CDMO Features
Figure 5. Global Peptide and Oligonucleotide CDMO Market Size Comparison by Application (2023-2033) & (US$ Million)
Figure 6. Global Peptide and Oligonucleotide CDMO Market Share by Application: 2022 VS 2033
Figure 7. Pharmaceutical and Biotechnology Companies Case Studies
Figure 8. Research Institutes Case Studies
Figure 9. Others Case Studies
Figure 10. Peptide and Oligonucleotide CDMO Report Years Considered
Figure 11. Global Peptide and Oligonucleotide CDMO Market Size (US$ Million), Year-over-Year: 2018-2033
Figure 12. Global Peptide and Oligonucleotide CDMO Market Size, (US$ Million), 2018 VS 2022 VS 2033
Figure 13. Global Peptide and Oligonucleotide CDMO Market Share by Region: 2022 VS 2033
Figure 14. Global Peptide and Oligonucleotide CDMO Market Share by Players in 2022
Figure 15. Global Top Peptide and Oligonucleotide CDMO Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Peptide and Oligonucleotide CDMO as of 2022)
Figure 16. The Top 10 and 5 Players Market Share by Peptide and Oligonucleotide CDMO Revenue in 2022
Figure 17. North America Peptide and Oligonucleotide CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 18. North America Peptide and Oligonucleotide CDMO Market Share by Country (2018-2033)
Figure 19. United States Peptide and Oligonucleotide CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 20. Canada Peptide and Oligonucleotide CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 21. Europe Peptide and Oligonucleotide CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 22. Europe Peptide and Oligonucleotide CDMO Market Share by Country (2018-2033)
Figure 23. Germany Peptide and Oligonucleotide CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 24. France Peptide and Oligonucleotide CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 25. U.K. Peptide and Oligonucleotide CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 26. Italy Peptide and Oligonucleotide CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 27. Russia Peptide and Oligonucleotide CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 28. Nordic Countries Peptide and Oligonucleotide CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 29. Asia-Pacific Peptide and Oligonucleotide CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 30. Asia-Pacific Peptide and Oligonucleotide CDMO Market Share by Region (2018-2033)
Figure 31. China Peptide and Oligonucleotide CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 32. Japan Peptide and Oligonucleotide CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 33. South Korea Peptide and Oligonucleotide CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 34. Southeast Asia Peptide and Oligonucleotide CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 35. India Peptide and Oligonucleotide CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 36. Australia Peptide and Oligonucleotide CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 37. Latin America Peptide and Oligonucleotide CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 38. Latin America Peptide and Oligonucleotide CDMO Market Share by Country (2018-2033)
Figure 39. Mexico Peptide and Oligonucleotide CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 40. Brazil Peptide and Oligonucleotide CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 41. Middle East & Africa Peptide and Oligonucleotide CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 42. Middle East & Africa Peptide and Oligonucleotide CDMO Market Share by Country (2018-2033)
Figure 43. Turkey Peptide and Oligonucleotide CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 44. Saudi Arabia Peptide and Oligonucleotide CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 45. Lonza Group Ltd. Revenue Growth Rate in Peptide and Oligonucleotide CDMO Business (2018-2023)
Figure 46. Thermo Fisher Scientific Inc. Revenue Growth Rate in Peptide and Oligonucleotide CDMO Business (2018-2023)
Figure 47. Merck KGaA Revenue Growth Rate in Peptide and Oligonucleotide CDMO Business (2018-2023)
Figure 48. Catalent, Inc. Revenue Growth Rate in Peptide and Oligonucleotide CDMO Business (2018-2023)
Figure 49. Genscript Biotech Corporation Revenue Growth Rate in Peptide and Oligonucleotide CDMO Business (2018-2023)
Figure 50. Polypeptide Group Revenue Growth Rate in Peptide and Oligonucleotide CDMO Business (2018-2023)
Figure 51. Bachem Holding AG Revenue Growth Rate in Peptide and Oligonucleotide CDMO Business (2018-2023)
Figure 52. Wuxi Apptec Co., Ltd. Revenue Growth Rate in Peptide and Oligonucleotide CDMO Business (2018-2023)
Figure 53. Ajinomoto Co., Inc. Revenue Growth Rate in Peptide and Oligonucleotide CDMO Business (2018-2023)
Figure 54. Rentschler Biopharma SE Revenue Growth Rate in Peptide and Oligonucleotide CDMO Business (2018-2023)
Figure 55. Corden Pharma GmbH Revenue Growth Rate in Peptide and Oligonucleotide CDMO Business (2018-2023)
Figure 56. Senn Chemicals AG Revenue Growth Rate in Peptide and Oligonucleotide CDMO Business (2018-2023)
Figure 57. Almac Group Revenue Growth Rate in Peptide and Oligonucleotide CDMO Business (2018-2023)
Figure 58. Lonza Custom Manufacturing Revenue Growth Rate in Peptide and Oligonucleotide CDMO Business (2018-2023)
Figure 59. Creative Peptides Revenue Growth Rate in Peptide and Oligonucleotide CDMO Business (2018-2023)
Figure 60. Swiss Customized Synthesis Revenue Growth Rate in Peptide and Oligonucleotide CDMO Business (2018-2023)
Figure 61. Syngene Revenue Growth Rate in Peptide and Oligonucleotide CDMO Business (2018-2023)
Figure 62. Eurogentec Revenue Growth Rate in Peptide and Oligonucleotide CDMO Business (2018-2023)
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed